Inflammation-based prognostic system predicts survival after surgery for stage IV colorectal cancer - 14/12/12
, Hitoshi Nagata, M.D., Kazutoshi Takagi, M.D., Yoshimi Iwasaki, M.D., Keiichi Kubota, M.D.
Corresponding author. Tel.: +81-282-87-2158; fax: +81-282-86-6317Abstract |
Background |
The aim of this study was to estimate whether the Glasgow prognostic score (GPS) is useful for predicting the survival of patients after surgery for stage IV colorectal cancer (CRC).
Methods |
The GPS was calculated on the basis of admission data as follows: patients with both an increased C-reactive protein (CRP) level (>1.0 mg/dL) and hypoalbuminemia (<3.5 g/dL) were allocated a score of 2, and patients showing one or none of these abnormalities were allocated a score of 1 or 0, respectively.
Results |
A total of 108 patients with stage IV CRC were enrolled. Although multivariate analyses showed that tumor pathology, subclass of stage IV CRC, and the GPS were associated with overall survival, the GPS could divide the patients into 3 independent groups showing significant differences in postoperative survival (P = .018).
Conclusions |
The GPS is not only one of the most significant clinical characteristics associated with the overall survival of patients with stage IV CRC, but also a useful indicator that is capable of dividing such patients into 3 independent groups before surgery.
Le texte complet de cet article est disponible en PDF.Keywords : Glasgow prognostic score, Postoperative survival, Stage IV colorectal cancer, Subclass, Systemic inflammatory response
Plan
| The authors have no conflicts of interest to declare. |
Vol 205 - N° 1
P. 22-28 - janvier 2013 Retour au numéro
Article précédent
- Radical tumor excision and immediate abdominal wall reconstruction in patients with aggressive neoplasm compromised full-thickness lower abdominal wall
- Fei Yang
- Predicting resource utilization of elderly burn patients in the baby boomer era
- Winston T. Richards, Winston A. Richards, Makeesha Miggins, Huazhi Liu, David W. Mozingo, Darwin N. Ang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?